Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #31 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Cohance Lifesciences Limited (this stock) | 17,093 | 96.3 | 3.0% | -48.6% | — | 56 | 18 | 66 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 422 | -43 | -45 | ₹ |
| March 31, 2026 | 619 | 20 | 8 | ₹ |
| Dec. 31, 2025 | 545 | 41 | 29 | ₹ |
| June 30, 2025 | 549 | 63 | 46 | ₹ |
| March 31, 2025 | 402 | 52 | 39 | ₹ |
| Dec. 31, 2024 | 307 | 110 | 83 | ₹ |
| Sept. 30, 2024 | 258 | 100 | 82 | ₹ |
| June 30, 2024 | 231 | 83 | 61 | ₹ |
| Dec. 31, 2023 | 220 | 65 | 47 | ₹ |
| Sept. 30, 2023 | 231 | 105 | 80 | ₹ |
| June 30, 2023 | 348 | 164 | 121 | ₹ |
| March 31, 2023 | 369 | 166 | 124 | ₹ |
| Dec. 31, 2022 | 354 | 146 | 108 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 2,269 | 207 | 150 |
| March 31, 2025 | 1,198 | 344 | 265 |
| March 31, 2023 | 1,340 | 560 | 411 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 368 | -255 | -165 | 220 | 148 |
| March 31, 2025 | 288 | -255 | 3 | 156 | 132 |
| March 31, 2023 | 451 | -195 | -236 | 286 | 165 |
| March 31, 2022 | 330 | -136 | -156 | 75 | 255 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 5,730 | 4,034 | 3,873 | 119 | 50 | 1,796 | 646 | 49 | 1,990 | 562 |
| March 31, 2025 | 3,032 | 1,841 | 1,671 | 72 | 6 | 853 | 365 | 85 | 995 | 167 |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
